Emergent BioSolutions Inc.
Company Stats
- Market Cap
- $338.4M
- as of Sep 30, 2026
- Shares Outstanding
- 51.3M
- Free Float
- 12.3%
Income Statement
- Revenue
- $742.9M
- Operating Income
- $100.1M
- Net Income
- $52.6M
- EBITDA
- $195.9M
- Revenue Growth, 3Y
- -12.7%
- FCF Margin, 3Y Avg
- -0.0%
- FCF Margin, Worst Year
- -24.6%
Cash Flow
- Free Cash Flow
- $156.8M
- FCF Yield
- 46.3%
- Owner FCF Yield
- 41.5%
Balance Sheet
- Cash & Equivalents
- $205.4M
Returns & Capital
- Share Repurchases
- $24.9M
- Buyback Yield, 3Y Avg
- 2.5%
- SBC, 3Y Avg
- $19.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $742.9M | $156.8M | 21.1% |
| FY2024 | $1.0B | $35.8M | 3.4% |
| FY2023 | $1.0B | -$257.9M | -24.6% |
| FY2022 | $1.1B | -$149.9M | -13.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back